Anavex life sciences reports publication of anavex®3-71 in clinical journal confirming anavex®3-71 clinical cardiovascular safety

New york, aug. 07, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced a peer-reviewed publication in clinical pharmacology in drug development, findings from the anavex®3-71 first-in-human study which achieved its cardiovascular safety objectives. the publication is entitled, ‘concentration-qtc relationship from a single ascending dose study of anavex3-71, a novel sigma-1 receptor and allosteric m1 muscarinic receptor agonist in development for the treatment of frontotemporal dementia, schizophrenia, and alzheimer's disease'. 1
AVXL Ratings Summary
AVXL Quant Ranking